Company’s 36-month beta value is 0.51.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LUNG is 35.22M, and currently, short sellers hold a 3.79% ratio of that floaft. The average trading volume of LUNG on June 18, 2025 was 375.78K shares.
LUNG) stock’s latest price update
Pulmonx Corp (NASDAQ: LUNG)’s stock price has decreased by -9.06 compared to its previous closing price of 2.98. However, the company has seen a -20.29% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-02 that Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard ratio [HR], 0.60; 95% confidence interval [CI]: 0.47, 0.77; P < 0.001).
LUNG’s Market Performance
Pulmonx Corp (LUNG) has seen a -20.29% fall in stock performance for the week, with a -20.99% decline in the past month and a -66.00% plunge in the past quarter. The volatility ratio for the week is 3.39%, and the volatility levels for the past 30 days are at 4.92% for LUNG. The simple moving average for the last 20 days is -13.71% for LUNG stock, with a simple moving average of -56.37% for the last 200 days.
Analysts’ Opinion of LUNG
Many brokerage firms have already submitted their reports for LUNG stocks, with D. Boral Capital repeating the rating for LUNG by listing it as a “Buy.” The predicted price for LUNG in the upcoming period, according to D. Boral Capital is $17 based on the research report published on March 10, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see LUNG reach a price target of $7.50, previously predicting the price at $17. The rating they have provided for LUNG stocks is “Neutral” according to the report published on December 11th, 2024.
Lake Street gave a rating of “Buy” to LUNG, setting the target price at $12 in the report published on June 04th of the previous year.
LUNG Trading at -30.97% from the 50-Day Moving Average
After a stumble in the market that brought LUNG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.08% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUNG starting from Ferrari Richard, who sale 8,000 shares at the price of $3.16 back on Jun 12 ’25. After this action, Ferrari Richard now owns 87,024 shares of Pulmonx Corp, valued at $25,280 using the latest closing price.
Ferrari Richard, the Director of Pulmonx Corp, proposed sale 5,438 shares at $3.01 during a trade that took place back on Jun 13 ’25, which means that Ferrari Richard is holding shares at $16,368 based on the most recent closing price.
Stock Fundamentals for LUNG
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.74 for the gross margin
The net margin for Pulmonx Corp stands at -0.65. The total capital return value is set at -0.46. Equity return is now at value -60.68, with -36.21 for asset returns.
Based on Pulmonx Corp (LUNG), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at -0.58. The debt to equity ratio resting at 0.73. The interest coverage ratio of the stock is -16.95.
Currently, EBITDA for the company is -50.79 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 1.05. The receivables turnover for the company is 5.99for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.97.
Conclusion
In a nutshell, Pulmonx Corp (LUNG) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
